CLChang-Lei Li

Chang-Lei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chang-Lei Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Zu-Sen Wang

    The Affiliated Hospital of Qingdao University

    2 shared publications
  • Ao Sun

    Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication
  • Ao-Yun Hao

    Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication
  • Chenyu Cao

    De Anza College, Cupertino, USA

    1 shared publication
  • Haozhuo Guo

    CAS Key Laboratory of Molecular Imaging Beijing Key Laboratory of Molecular Imaging Institute of Automation Chinese Academy of Sciences Beijing China

    1 shared publication
  • Huadan Xue

    Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Combined Immune‐Peptide Nanofiber with HSP70/AKT/mTOR Axis Blockade Enhances Photothermal Immunotherapy, Inhibiting Tumor Growth and Recurrence

    by Xinyu Zhang, Zhenqi Jiang, Wenjia Zhang, Juncheng Wu, Haozhuo Guo, Changlei Li, Mingwei Sun, Xiaoying Tang, Yue Zhang, Wei Huang, et al.

    Although immune checkpoint blockade (ICB) therapies have shown clinical benefit, ICBs exert limited effects on most “immune‐cold” solid tumors, i.e., tumors with low immune infiltration. Photothermal immunotherapy (PTIT) converts “cold” tumors into “hot” tumors, thereby enhancing immune responses and improving ICB efficacy. Hence, developing a strategy that can integrate PTIT and ICB treatment is desirable. In this study, we designed a unique carrier‐free PSP@IR‐CF 3 nanofiber, self‐assembled from the programmed death‐ligand 1 (PD‐L1) targeting immune‐peptide NTGYFYGDQ (PSP) and a PTIT agent (IR‐CF 3 ). The nanofibers enable precise tumor targeting and immune checkpoint inhibition by specifically binding to PD‐L1 on the tumor cell surface, also providing an NIR‐mediated photothermal effect. Combining PSP@IR‐CF 3 nanofibers with NIR induced mild PTIT, which effectively activated the tumor immune microenvironment and suppressed tumor growth with lower immunotoxicity. Additionally, we identified activation of the heat shock protein 70 (HSP70) /AKT/mTOR axis following PTIT, suggesting a potential role in post‐treatment tumor survival and recurrence. By incorporating the mTOR inhibitor rapamycin, the combination treatment further enhanced therapeutic efficacy and reduced tumor recurrence.

  • Open Access

    Antihypertensive drug targets and pancreatitis reporting signals: An integrative mendelian randomization and FAERS pharmacovigilance study

    by Chang-Lei Li, Si-Han Wang, Zhi-Yuan Yao, Xiao-Tong Cui, Zu-Sen Wang

    Objective: To investigate whether genetically proxied antihypertensive drug targets are associated with pancreatic exocrine diseases and whether corresponding antihypertensive agents show pancreatitis-related pharmacovigilance signals. Methods: This integrative genetic epidemiology and pharmacovigilance study combined linkage disequilibrium score regression, two-sample Mendelian randomization, summary-data-based Mendelian randomization, Bayesian colocalization, and FAERS disproportionality analysis. Publicly available GWAS summary statistics were derived predominantly from European-ancestry participants, and whole-blood cis-eQTLs were used to genetically proxy antihypertensive drug-target expression. FAERS reports submitted from 2004 to 2023 were analyzed for pancreatitis-related reporting signals. Results: Among 21 antihypertensive drug targets, ADRB2, CACNA1I, JUN, NR3C2, and SLC12A4 showed nominal associations with pancreatic outcomes; however, none remained significant after Bonferroni correction. Absolute PP.H4 values did not support robust colocalization. Although several target-outcome pairs had high conditional PP.H4 values, these findings provide only relative support for H4 over H3 when both traits are assumed to have regional association signals. Several antihypertensive agents also generated pancreatitis-related reporting signals in FAERS; these signals do not quantify incidence or establish causality. Conclusions: The findings are exploratory and prioritize selected antihypertensive targets and drugs for replication and mechanistic study. They do not establish causal effects, robust colocalization, or an increased incidence of pancreatitis.

  • Open Access

    Identification of MMEL1 as a novel therapeutic target for primary sclerosing cholangitis: Integrating Mendelian randomization and transcriptome landscapes

    by Chang-Lei Li, Ao Sun, Yu-Kun Liu, Rui-Tao Sun, Ao-Yun Hao, Ying-Ying Lan, Jing-Yu Cao, Zu-Sen Wang

    Primary sclerosing cholangitis (PSC) is a kind of cholestatic liver disease without effective targeted therapies, and its pathogenesis remains largely unclear. We performed genome-wide Mendelian randomization analysis to identify therapeutic targets PSC risk. Summary statistics for PSC were obtained from 2 datasets: the International PSC Study Group (2871 cases and 12,019 controls) and the FinnGen cohort (1483 cases and 361,641 controls). Cis-expression quantitative trait loci for druggable genes were extracted from the eQTLGen Consortium and Genotype-Tissue Expression Version 8 database and applied as genetic instrumental variables. Colocalization analysis was performed to estimate the probability that single nucleotide polymorphisms associated with PSC and eQTLs shared causal locus. Six drug targets (APOM, BTN3A2, HLA-DRA, membrane metalloendopeptidase like 1 [MMEL1], NEU1, and RXRB) presented significant Mendelian randomization results in 2 independent datasets. MMEL1, of which eQTLs resourced from blood, liver, transverse colon, and intestine, was all found to have strong evidence for colocalization with PSC. Genetically proxied inhibition of MMEL1 was also detected to attenuate the risk of immune bowel diseases and ulcerative colitis. A transcriptome-wide associated study presented consistent inference, as shown above. Our study highlighted 1 candidate druggable target (MMEL1 for PSC development and prognosis).